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MITHRAMYCIN is an antibiotic with cytotoxic activity derived from an
actinomycete of the Streptomyces genus. The drug acts like Actinomycin D by
inhibiting DNA directed RNA synthesis (Yarbro, Kennedy and Barnum, 1966).
There have been several clinical trials of this drug reported by American
workers (Parker, Wiltsie, and Jackson, 1960; Spear, 1963; Kofman and
Eisenstein, 1963; Hurley, 1965), but so far only 1 trial reported from the United
Kingdom (Sewell and Ellis, 1966).
Mithramycin appears to have a broad spectrum of activity but to date its
importance has only been established in the treatment of testicular neoplasms
(Kennedy, Griffen and Lober, 1965; Brown and Kennedy, 1965).
Design of trial
The present trial was conducted as a phase II investigation ofa new anticancer
agent according to the methodology of Brindley (1963). In phase I the toxic
side effects of a new drug are established and a safe dosage schedule worked out.
In phase II a large number of tumour types are screened for any evidence of
antitumour activity however minimal. Then phase III trials are undertaken to
follow up this evidence in a specific tumour type.
For a phase II trial the followving criteria have to be met for each patient
entered.
A. Incurable cancer which has failed to respond to previous conventional
therapy.
B. Histological proof of diagnosis.
C. One or more of the following for the objective assessment of tumour
regression.
(i) Palpable tumour masses withwelldefined margins which canbe measured
by caliper or ruler.
(ii) Multiple lesions that can be counted.
(iii) Well defined bony or lung metastases that can be measured on an X-ray.
(iv) A tumour-specific biochemical abnormality which can be measured
quantitatively.
D. At least 1 month since prior treatment by cytotoxic drugs or radiotherapy.
E. No evidence ofbone marrow depression or renal failure. No patients with,
a white cell count of less than 3500/mm.3, a platelet count of less than 100,000/
mm.3, or a blood ureaof more than 40 mg./100 ml. were admitted to this particular
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Therapeutic regime
The dosage and method of administration was similar to that recommended
by Brown and Kennedy (1965). The drug waskept at-10° C. in vials containing
2-5 mg. of the crystalline material. 4-9 ml. of sterile water were used to dissolve
the crystals, the resulting solution containing 0-5 mg. of Mithramycin/ml.
25 ,ug./kg. body weight of the solution were added to 500 ml. of 5 % dextrose and
given slowly by continuous intravenous infusion over 12 hours. The drip was
then kept open with another bottle of 5 % dextrose to complete the 24 hours
before the next dose. If possible a 25jig./kg. dose was given in each 24 hour
period for 8 days. Sometimes the coursewasinterrupted formildtoxicsymptoms,
or to give the patient " a rest " and occasionally the course had to be terminated
because ofthe onset of severe toxic symptoms.
Laboratory investigations
Regular laboratory investigations were carried out before, during and for some
days after the course oftherapy according to Table I.
TABLE I.-Laboratory Investigations
Time Interval Investigation
Daily . Haemoglobin, total and differential white cell count
and platelet count. Serum calcium and phosphorus.
Urinary calcium, hydroxyproline and creatinine.
Alternate days (starting a week . Serum lactic dehydrogenase (LDH), glutamic oxalic
before and ending a week after transaminase (SGOT), glutamic pyruvic transaminase
treatment). (SGPT) and alkaline phosphatase (SAP)
Three day intervals . Blood urea and electrolytes.
Assessment of results
The response to treatment was assessed by measuring or counting the tumours
before and 2 days after the course oftherapy. The grading ofthe results is shown
in Table II.
TABLE II.-Assessment ofResponse to Treatment
Major regression . 50% or more reduction in size or number of
lesions.
Minor regression . Measureable reduction in size of tumour of
less than 50% or reduction in number of
lesions less than 50%.
No change . No change in size or number oflesions.
Progression . Increase in size or number of lesions.
As some of the more interesting responses to the drug could not be classified
adequately on this basis alone, special mention of individual cases will be made
later in the paper. Duration ofresponse was not recorded as this was not thouaht
to be relevant to this phase of a trial.
Subjective responses were recorded and will be commented on in individual
cases but no attempt to classify these on a numerical scale was made.
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RESULTS
Thirty-two patients were treated, 20 females and 12 males. The mean age
ofthe group was 61 years and ranged from 42 years to 83 years. Eleven patients
toleratedthefull 8day course and 1 patient had 2 full coursesseparatedby 1 month.
Fifteen patients had courses lasting 4 to 7 days and 6 patients had less than 4 days'
treatment. The daily dose of Mithramycin ranged from 0 9 mg. to 2-0 mg. and
the total dose of the drug ranged from 1-4 mg. to 14 mg. with a mean total dose
of 8-8 mg.
The sites of the primary tumours and their histology, the number of days of
treatment and the response to treatment, are listed in Table III.
TABLE III
Histology
Myeloma
Spheroidal cell carcinoma
Adenocarcinoma
Squamous cell carcinoma
Adenocarcinoma
Anaplastic carcinoma
Squamous cell carcinoma
Adenocarcinoma
,,
Spheroidal cell carcinoma
Adenocarcinoma (hepatic metastases)
Adenocarcinoma
Fibrosarcoma
Adenocarcinoma
Squamous cell carcinoma
Adenocarcinoma
Squamous cell carcinoma
Anaplastic carcinoma
Fibrosarcoma
Adenocarcinoma
Number of
Days of
Treatment Response
8 . No change
2 . Minor regression
7 . Progression
6 . Minor regression
8 . No change
7 . Progression
7 . Minor regression
7 . Progression
4 . No change
6 . Major regression
8 . Minor regression
8 .
7 .
7 . No change
6 . Minor regression
2 . No change
8 . Progression
1
1 . ,
8
2
8 . Minor regression
3 Progression
8 x 2 . No change
8
8 .
7
8 . Progression
6 . No change
8 . ..
4 . Minor regression
6 . No change
There was 1 major regression occurring in a patient with carcinoma of the
rectum. Nine minor regressions were recorded, 5 from patients with carcinoma
of the breast and 1 each from patients with carcinoma of the rectum, carcinoma
of the uterus, fibrosarcoma and hepatic secondaries. There was no apparent
relation between length of treatment and response, indeed, most recorded regres-
sions became obvious after only 2 or 3 days oftherapy.
Ten patients died within 2 weeks of therapy, giving some indication of the
advanced nature of the disease in a large proportion of the cases admitted to the
trial.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Site of
Primary
Bone Marrow
Breast
Rectum
Bronchus
Breast
Bronchus
Rectum
Breast
Uterus
Breast
Rectum
Pancreas
Rectum
Pancreas
Ovary
Breast
Unknown
Breast
Pelvis
Rectum
Mouth
Kidney
Bronchus
Bronchus
Pelvis
Leg
Breast
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Subjective improvement was commonly met with but difficult to interpret. A
feeling of well-being could easily be accounted for on psychological grounds,
resulting from the renewed interest shown in a patient who probably sensed that
hope had been abandoned in their case. In addition to this, however, several
patients who showed no objective signs of tumour regression noted marked
improvement in their pain, leading to a reduced intake of analgesics. This could
possibly be due to neurotoxicity as seen with other anticancer agents such as
methotrexate (Woodhall, Mahaley, Boone and Huneycutt, 1962). We have been
unable to confirm this yet with animal experiments.
Illustrative case histories
(1) A.C.-male aged 65.-He presented with a 3 month history of change in
bowel habit. An abdomino-perineal resection was performed for carcinoma ofthe
rectum. At operation the growth extended through the bowel wall. Six months
later he returned complaining of perineal pain and urinary incontinence. There
was a massive pelvic recurrence extending into the perineum as a superficial
ulcerated lesion 8 cm. X 4 cm. He was given a course of Mithramycin but this
had to be stopped after 6 days because of vomiting, although his platelet count
remained above 100,000 cm. Following this the perineal growth became necrotic
and his pain completely disappeared. Two days after finishing treatment he
developed purpura and ecchymoses and started bleeding from the gums. A
platelet count atthis timewas 16,000 cm. Hewas put onlargedosesofprednisone
and within 5 days his platelet count had returned to within normal limits. How-
ever, he died a week later. Post mortem showed that the cause of death was
bronchopneumonia butsections ofthepelvictumour showedextensive antemortem
necrosis.
Comment: This case illustrates the principal danger ofthe drug, although the
thrombocytopenia in this case did not occur while the drug was being given.
(2) N.C.-female aged 59.-A curettage to find the cause of post-menopausal
bleeding confirmed the diagnosis of adenocarcinoma of the uterus. This was
treated by a total hysterectomy and bilateral salpingo-oophorectomy from which
she made a good recovery. Ten months later a pelvic recurrence was treated with
radiotherapy. After a further 2 months she was admitted with right sided
weakness, pains in the back, a severe headache and vomiting. A gamma scan of
the brain using radioactive mercury confirmed the presence ofcerebral metastases.
She was given a full course ofMithramycin. After 2 days she developed cerebral
oedema but this improved after a further 48 hours and by the end of the 8th day
course, she was feeling well, free of pain, alert and active with a good appetite.
There was some objective improvement in her C.N.S. signs as well. A constant
fluid intake was maintained throughout so it was unlikely that the improvement
resulted from inadvertent dehydration therapy. She maintained her subjective
improvement for about 6 weeks and then slowly deteriorated and died a further
month later.
Comment: Regression of cerebral metastases has been noted before with
Mithramycin (Kofman and Eisenstein, 1963).
(3) W.S.-male aged 64.-A year before being referred for treatment he had a
below knee amputation for a fibrosarcoma of low grade malignancy arising in the
soft tissuesaroundthe ankle. Fourmonths after this he developedlungmetastases
and was started on Methotrexate 5 mg. daily. Whilst on this therapy, metastatic
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deposits appeared in the amputation stump, in the groin, in the skin and in both
humeri. Methotrexate was stopped and he was given repeated courses of radio-
therapy without significant response.
In November, 1966 he was started on Mithramycin. After 3 doses the deposit
in the amputation stump became necrotic and sloughed. After a further dose he
developed massive ascites and bilateral pathological fractures of both humeri.
Abdominal paracentesis revealed blood and necrotic debris. He died 3 days later.
Post mortem examination showed massive peritoneal deposits all of which had
undergone necrosis and both humeri were almost entirely replaced by necrotic
tumour.
Comment: In this case the tumour was obviously highly sensitive to the drug
but the sudden necrosis ofsuch a large mass ofmalignant tissue contributed to his
death.
(4) A.S.-male aged 63.-In 1961 he had an abdomino-perineal resection ofthe
rectum performed for adenocarcinoma. In January, 1966 he was readmitted
because ofweight loss and perineal pain. On examination a hard fixed mass was
noticed in the left iliac fossa extending 10 cm. above the anterior superior iliac
spine and his liver extended 4 finger breadths below the costal margin. He was
given a course ofMithramycin which was stopped after 6 days because ofvomiting,
weakness and dizziness. During treatment his pain disappeared completely and
the massinthe left iliacfossareducedin size. Bythe end ofthe course itextended
6 cm. above the iliac spine and 3 months later it had reduced to a mobile lump
3 cm. in diameter. He was able to return to work and has remained well until
the time of writing-18 months later. However, the mass in his left iliac fossa
has increased in size again and he has developed a metastasis in his buttock.
Comment: In retrospect this was the only patient in whom we achieved
worthwhile regression. There has been a long-lasting subjective improvement as
well as objective signs oftumour regression, at the expense ofonly mild and short-
lived toxic side effects.
Toxicity
The incidence of toxic side effects is summarized in Table IV.
TABLE IV.-Incidence ofToxic Side Effects
Toxic symptoms No. of Patients
None 10
Anorexia and nausea . 9
Severe vomiting . 5
Thrombocytopenia . 4
Diarrhoea . 3
C.N.S. symptoms 3
Thrombophlebitis . 3
Toxic symptoms were relatively common and only 10 patients tolerated a full
course without any unpleasant side effects. The commonest toxic symptoms
were anorexia and nausea which were usually easy to control without the necessity
ofterminating the course oftreatment. Uncontrollable vomiting was met with in
5 cases and was an absolute indication to stop therapy. Thrombocytopenia
occurred in 4 patients and is probably the most dangerous side effect. In 2
patients the platelet count fell during therapy and rapidly returned to normal
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without ill effect on witholding the drug. In another 2 thrombocytopenia
developed 2 days after the end of a course of Mithramycin and both developed
purpura and bleeding. Steroid therapy was successful in correcting both. They
emphasise the importance ofdaily platelet counts before, during and after therapy
withMithramycin.
Leucopenia never occurred but an unexplained polymorph leucocytosis was
often seen. Severe diarrhoea troubled 3 patients and a further 3 developed C.N.S.
symptoms such as drowsiness and dizziness.
The infusion caused a local thrombophlebitis in 3 patients and as this recurred
afterrepeatedrepositionings oftheinfusion it was probably atrue effect ofthedrug
and not just due to faulty technique.
On no occasion was conclusive laboratory evidence of liver or kidney damage
encountered.
Changes in serum isoenzyme levels
In order to test the drug for hepatotoxicity, liver function tests were carried
out on patients before and during therapy. In particular SGOT, SGPT, LDH
and SAP levelswere carefullywatched. Anoccasionalpatientdeveloped amarked
rise in LDH levels in the absence of a comparable rise in the levels of the other
enzymes studied, and in the absence ofotherlaboratory evidence ofliver damage.
Fractionation ofthe LDH into anaerobic and aerobic (heat labile and heat stable)
components suggested that the major source of increase was in the anaerobic
fraction, i.e. from an extrahepatic source. Similar findings have been noticed by
other workers (Brown and Kennedy, 1965; Medrek, 1966, personal communi-
cation). Tumour cell necrosis probably causes the increase in serum LDH levels,
which is suggested by the fact that all but one ofthe present series ofpatients who
showed objective signs oftumour regression developed elevated LDH levels. The
converse was also true. None of the patients without evidence of tumour re-
gression developed similar changes in isoenzyme levels. The patient illustrated
in Fig. 1 shows atypical pattern associated with tumourresponse. As the enzyme
changes preceded the objective signs of regression, serial estimations of serum
LDH might be used as evidence of tumour sensitivity to Mithramycin. Holsti
(1965) has already suggested a similar method to assess the response of a tumour
to radiotherapy.
Effect on calcium metabolism
The effect ofMithramycin on calcium metabolismwasfirstnoticed byJacobsen,
Holmes, Petersen andEnbring (1965). The changes in calcium metabolismduring
this trial were investigated fully and have already been reported (Parsons, Baum
and Self, 1967).
Our findings suggested that Mithramycin blocked the peripheral action of
parathyroid hormone or vitamin D on gut and bone leading to a consistent hypo-
calcaemic effect and a striking fall in urinary calcium excretion. We have treated
a patient in whom disseminated malignant disease caused a life threatening
hypercalcaemia of 17 mg./100 ml. After 48 hours therapy with Mithramycin
it fell to 9 5 mg./100 ml. The serum calcium continued to fall to 5-5 mg./100 ml.
butreturnedto normal onwithholding thedrug. Unfortunatelytheplatelet count
started to fall and further doses of Mithramycin were not given and the serum
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FIG. 1.-Serum isoenzyme changes occurring in association with Mithramycin therapy-see
case history (1).
LDH-Lactic dehydrogenase
SGOT-Serum glutamic oxalic transaminase
SGPT-Serum glutamic pyruvate transaminase
calcium returned to supra normal levels. On this evidence it is suggested that
Mfithramycin may turn out to be a useful drug in the emergency treatment of
hypercalcaemia.
CONCLUSION
All cases referred to this trial were in very advanced stages of malignant
disease having recurred after, or failed to respond to, conventional therapy.
Because of this it would have been unrealistic to have expected any long term
remissions. However, any evidence oftumour sensitivity is interesting and would
suggest that a more intensive study ofthat specific tumour type would be worth-
while as a phase III trial. From our experience therefore it is suggested that
Mithramycin should be further investigated for its effect on the following: car-
cinoma ofthe breast, carcinoma of the rectum, fibrosarcoma, cerebral metastases
and hepatic metastases.
Unfortunately the drug has serious side effects and these were often seen in the
very cases that seemed to show tumour sensitivity. In view of this it would
perhaps be more ethical to await the development of a readily available method
of testing a tumour sample for sensitivity against a battery of chemotherapeutic
agents (Knock, 1967).
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SUMMARY
1. Thirty-two patients with advanced malignant disease were treated with
Mithramycin.
2. One patient had a major regression ofhis disease and 8 patients had signifi-
cant minor regressions.
3. The toxic effects of the drug are recorded.
4. Changes in serum isoenzyme levels during treatment and the effect of
Mithramycin on calcium metabolism are discussed.
5. It is suggested that more detailed studies ofthe use ofthe drug for the treat-
ment of carcinoma of the breast, carcinoma of the rectum, fibrosarcoma, cerebral
metastases and hepatic metastases are undertaken.
Mithramycin was supplied through Pfizer Ltd., Sandwich, by the John L.
Smith Memorial for Cancer Research-Chas. Pfizer & Co. Inc., Maywood, New
Jersey, U.S.A., where the compound was produced under contract PH 43/64/50,
with collaborative research U.S. National Cancer Institute, U.S. Public Health
Service.
The authorwassupportedby agrantfromtheBritishEmpire Cancer Campaign
for Research.
I am indebted to the consultant and nursing staff of the King's College
Hospital Group, withoutwhose co-operation this studywouldhavebeenimpossible.
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